The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 19 of the 49 sources its claims cite were checked for support.
Abstract
This study aimed to investigate the influence of genetic variants in neuroplasticity-related genes on antidepressant treatment phenotypes. The BDNF-TrkB signaling pathway, as well as the downstream kinases Akt and ERK and the mTOR pathway, have been implicated in depression and neuroplasticity. However, clinicians still struggle with the unpredictability of antidepressant responses in depressed patients. We genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 in 80 patients with major depressive disorder treated according to the Texas Medical Algorithm for 27 months at Hospital Magalhães Lemos, Porto, Portugal. Our results showed that BDNF rs6265, PTEN rs12569998, and SYN1 rs1142636 SNP were associated with treatment-resistant depression (TRD). Additionally, MAPK1 rs6928 and GSK3B rs6438552 gene polymorphisms were associated with relapse. Moreover, we found a link between the rs6928 MAPK1 polymorphism and time to relapse. These findings suggest that the BDNF, PTEN, and SYN1 genes may play a role in the development of TRD, while MAPK1 and GSK3B may be associated with relapse. GO analysis revealed enrichment in synaptic and trans-synaptic transmission pathways and glutamate receptor activity with TRD-associated genes. Genetic variants in these genes could potentially be incorporated into predictive models of antidepressant response.
Overview
CoChat Summary
TL;DR
In 80 Portuguese patients with major depressive disorder followed for 27 months on the Texas Medication Algorithm, polymorphisms in BDNF, PTEN, and SYN1 were associated with treatment-resistant depression, while MAPK1 and GSK3B were associated with relapse. Functional enrichment implicated synaptic and trans-synaptic transmission and glutamate receptor activity.
Key findings
- BDNF rs6265 CT genotype was associated with TRD (OR: 3.2; 95% CI: 0.975–10.501; p = 0.049); PTEN rs12569998 TG genotype was associated with TRD (OR: 4.231; 95% CI: 1.173–15.261; p = 0.020); SYN1 rs1142636 GG genotype was associated with TRD (OR: 6.00; 95% CI: 1.543–23.333; p = 0.006), as was the G allele (OR: 3.120; 95% CI: 1.045–9.314; p = 0.037).
- MAPK1 rs6928 C allele carriers had reduced relapse risk (OR: 0.303; 95% CI: 0.090–1.020; p = 0.048) and relapsed later than GG carriers (100 vs. 82 weeks, p = 0.022, log-rank).
- GSK3B rs6438552 GG genotype was associated with relapse (OR: 6.667; 95% CI: 1.121–39.660; p = 0.042), as was the G allele (OR: 5.600; 95% CI: 1.137–27.571; p = 0.033).
- GO analysis of TRD-associated genes showed enrichment in chemical synaptic transmission, anterograde trans-synaptic signaling, glutamate receptor signaling, neuron projections, dendrites, and ionotropic glutamate receptor complexes.
Methods
- Candidate-gene pharmacogenetic cohort study of 80 MDD patients recruited at Hospital Magalhães Lemos, Oporto, Portugal, followed for 27 months and treated according to the Texas Medication Algorithm; diagnosis used SCID-I and severity used BDI. Evaluated phenotypes included remission, TRD, time to remission, relapse, and time to relapse.
- Genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 using the Sequenom MassARRAY platform; 10% of samples were repeated for quality control with the same results.
- Statistical analysis used chi-square tests, odds ratios with 95% confidence intervals, Kaplan–Meier survival curves with log-rank tests, and Hardy–Weinberg equilibrium testing; Geneshot and Enrichr were used for GO and KEGG enrichment analyses.
Limitations
- The paper states the sample is small, so small effects of single SNPs may not be detected; only a few SNPs per gene were evaluated due to the target-pathway design; and because drugs with different mechanisms of action were used, each SNP could not be correlated with a specific antidepressant class.
- Evident from the text: no correction for multiple comparisons is reported despite testing 26 polymorphisms across multiple treatment phenotypes, and the findings are candidate-gene associations in a small cohort that require replication.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
17 Valid · 1 Not valid · 14 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to the lag time between AD and clinical improvement, there are still about 30% of MDD patients who do not present improvements upon AD treatment, displaying a TRD phenotype [26].”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
What the sources say
- Partly supportedcites [26] Smith D.F. Quest for biomarkers of treatment-resistant depression: Shifting the paradigm toward risk Front. Psychiatry 2013 4 57 10.3389/fpsyt.2013.00057 23785338 PMC3684787 sourceExperimental — accuracy not yet measured
The Definitions of TRD section (page unavailable) describes treatment-resistant depression as major depressive disorder that has not improved after at least two adequate antidepressant trials. The Concluding Remarks (page unavailable) say treatment fails to relieve symptoms in many cases, but the paper does not give the claimed figure of about 30%. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the action of esketamine on AMPA receptors may ultimately improve neural plasticity and synaptogenesis through signaling pathways resulting in enhanced BDNF production [62].”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
What the sources say
- Supportedcites [62] Salahudeen M.S. Wright C.M. Peterson G.M. Esketamine: New hope for the treatment of treatment-resistant depression? A narrative review Ther. Adv. Drug Saf. 2020 11 2042098620937899 10.1177/2042098620937899 32782779 PMC7383653 source
The Pharmacology section states the claim almost verbatim, including its qualification that esketamine’s action on AMPA receptors may improve neural plasticity and synaptogenesis through signaling pathways that enhance BDNF production. (LLM, conf=0.95)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Peculiarly, a great majority of these TRD patients improve upon ketamine administration [27].”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
What the sources say
- Supportedcites [27] Serafini G. Howland R.H. Rovedi F. Girardi P. Amore M. The role of ketamine in treatment-resistant depression: A systematic review Curr. Neuropharmacol. 2014 12 444 461 10.2174/1570159X12666140619204251 25426012 PMC4243034 source
The Discussion states that ketamine has a rapid antidepressant effect in most TRD patients after a single infusion. The Results report response rates of 70.8%, 71%, and 91.6% in individual studies, supporting the claim that a large majority improve. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, in the cellular component category, neuron projections (GO:0043005), dendrites (GO:00340425), and ionotropic glutamate receptor complexes (GO:0008328) were the top enriched terms (Table 2).”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 2. Results > 2.3. Gene Functional Enrichment Analysis
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, no differences were found regarding time to remission for any of the evaluated SNPs.”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 2. Results > 2.2. Treatment Resistant Depression Phenotype
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 68 claims and to verify the 7 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 16
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 3. Discussion
“Concerning SYN1 polymorphism rs114263, carriers of the GG genotype had a six-fold risk of presenting a TRD phenotype”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 2. Results > 2.2. Treatment Resistant Depression Phenotype
“Additionally, there was a statistically significant association between rs1142636 of the SYN1 gene and TRD.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > 4. Materials and Methods > 4.1. Patients
“Time to remission (TRD), time to relapse (TR), remission, and TRD were the evaluated AD treatment response phenotypes.”
§ The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes > Abstract
“Our results showed that BDNF rs6265, PTEN rs12569998, and SYN1 rs1142636 SNP were associated with treatment-resistant depression (TRD).”
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“In fact, the rs6265 (Val66Met) has been demonstrated to alter pro-BDNF processing and, consequently, the secretion of BDNF [10], as well as the hippocampal volume [11].”
BackgroundGene set knowledge discovery with enrichr
Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L., Lachmann, A., Wojciechowicz, M. L., Kropiwnicki, E., Jagodnik, K. M., et al. (2021) · Current Protocols · doi:10.1002/cpz1.90 · Cited by 3,451 · cited 1×
“…enrichment analysis together with the genes identified as associated with TRD in the present study (BDNF, SYN1, and PTEN) to perform GO and KEGG Pathway analyses with Enrichr (https://maayanlab.cloud/Enrichr/ accessed on 26 march 2023), according to the protocol described by Xie, 2021 et al. [68].”
MethodmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 7×
“Several polymorphisms in genes involved in several neurotrophic/neuroplasticity pathways were evaluated, namely BDNF (rs1491850, rs204946, rs6265, rs908867), CREB1 (rs11904814, rs2253206, rs6740584, rs889895), NTRK2 (rs1187323, rs1187326, rs1387926, rs1778929, rs1565445, rs1659412), NGFR (rs11466155, rs2072446, rs7341…”
BackgroundInfluentialA molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform
Gabriel, S., Ziaugra, L., & Tabbaa, D. (2009) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0212s60 · Cited by 969
Castrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864 · cited 1×
“The TrkB activation induces downstream pathways, including the PI3K/Akt pathway, which is linked to the Wnt/β-catenin and to the mTOR pathway [4,16].”
BackgroundEssential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685
Cited by
From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine
Toader, C., Șerban, M., Munteanu, O., Covache-Busuioc, R.-A., Enyedi, M., Ciurea, A. V., & Tătaru, C. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094271 · Cited by 185
Numakawa, T., & Kajihara, R. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1247422 · Cited by 96
Jain, N. K., Tailang, M., Chandrasekaran, B., Khazaleh, N., Thangavel, N., Makeen, H. A., Albratty, M., Najmi, A., Alhazmi, H. A., Zoghebi, K. A., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1290398 · Cited by 44
Liu, J., Zhou, S., Wang, Y., Liu, J., Sun, S., Sun, Y., Xu, P., Xu, X., Zhu, B., & Wu, H. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116604 · Cited by 20
Minbay, M., Khan, A., Ghasemi, A. R., Ingram, K. K., & Ay, A. A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115948 · Cited by 16
Paolini, M., Fortaner-Uyà, L., Lorenzi, C., Spadini, S., Maccario, M., Zanardi, R., Colombo, C., Poletti, S., & Benedetti, F. (2023) · Genes · doi:10.3390/genes14112037 · Cited by 13
“Concerning antidepressant response, while some studies fail to identify an association with polymorphisms mapping to the NTRK2 gene [49,50], others do report such an association [51,52].”
ResultBommaraju, S., Dhokne, M. D., Arun, E. V., Srinivasan, K., Sharma, S. S., & Datusalia, A. K. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110943 · Cited by 12
Sherwani, M. K., Khan, J., Zainab, S. R., Mazhar, M. U., Ghazanfar, S., & Tipu, M. K. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153882 · Cited by 6
Santos, M., Lima, L., Carvalho, S., Brandão, A., Barroso, F., Cruz, A., & Medeiros, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105112 · Cited by 5
“Treatment-resistant depression was identified when a patient failed to attain a BDI score below 10 and continued to meet SCID-I criteria for MDD after undergoing at least two adequate antidepressant treatments with different drugs within the current episode [32].”
MethodSelf-citationAbnormal Serum BDNF and p-mTOR in MDD in Adolescents with Childhood Trauma
Zhao, X., Jie, H., Wang, J., Liu, Y., Liu, Y., Qin, F., Long, Q., Hou, X., Zhang, X.-W., Wu, W., et al. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s454370 · Cited by 7
“25 So, it is clear that BDNF is involved in the pathogenesis of MDD. Intriguingly, BDNF Val66Met polymorphism is also thought as an independent risk factor for MDD suicide attempts.”
BackgroundRole of Genetic and Epigenetic Biomarkers in Treatment-Resistant Depression: A Literature Review
Sulić, P., Pavičić, A. R., Ivančić, B. Đ., Božina, T., Božina, N., & Živković, M. (2025) · Genes · doi:10.3390/genes16121443 · Cited by 9
“Candidate gene analyses associate polymorphisms in BDNF , NTRK2 , PTEN , SYN1 , MAPK1 , and GSK3B with TRD and relapse [44].”
InfluentialMilasauskiene, E., Burkauskas, J., Jesmanas, S., Gleiznienė, R., Borutaitė, V., Škėmienė, K., Vaitkienė, P., Adomaitienė, V., Lukoševičius, S., Gradauskienė, B., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311218 · Cited by 3
Verma, A. K., Roy, B., & Dwivedi, Y. (2025) · Genomic psychiatry : · doi:10.61373/gp025h.0107 · Cited by 4
Phenylpropanoid-rich maize root extract serves as a natural antidepressant
Zhong, T., Zhang, Y., Yang, H., Luo, F., Xu, Y., Fan, Y., & Liu, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155893 · Cited by 3
Luo, Z., Mei, Y., Qi, Y., Huang, Y., Wang, X., Chen, X., & Jiang, W. (2025) · Obesity Reviews · doi:10.1111/obr.70027 · Cited by 1
Liao, D., Zhang, M., Yang, Q., Li, T., Cao, Z., Liu, D., Zhang, Z., Li, X., Tian, Z., Li, X., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2025.2610559 · Cited by 1
“MAPK signalling contributes to neuroplasticity and disruption of synaptic function, with implications for the development and progression of psychiatric disorders [35].”
Goel, I., Hans, G., Kumar, N. K., & Karmakar, S. (2024) · medRxiv · doi:10.1101/2024.11.25.24317869
“( Sforzini, L., et al., 2024; Marlene et al., 2023; Caspi, A. et al., 2003).”
Candidate Key Proteins of Tinnitus in the Auditory and Motor Systems of the Thalamus
Gross, J., Knipper, M., & Mazurek, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125804 · Cited by 3
“CREB1 (cAMP Response Element-Binding Protein 1) is a transcription factor that promotes the transcription of genes important for synaptic plasticity and LTP [53].”
Postu, P. A., Mihăşan, M., Gorgan, D. L., Stache, A. B., Sadiki, F. Z., Idrissi, M. E., & Hriţcu, L. (2026) · Applied Sciences · doi:10.3390/app16010511
Qi, S., Wang, D., Wu, Y. W., et al. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154210
Metadata
- Authors
- Santos, M., Lima, L., Carvalho, S., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Barroso, M. F., Gomes, S., Cruz, A., & Medeiros, R.
- Affiliations
- IPO Porto (PT)
- Experimental Pathology and Therapeutics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072 Porto, Portugal
- Hospital de Magalhães Lemos (PT)
- Clínica Médico-Psiquiátrica da Ordem, 4000-270 Porto, Portugal
- Unidade Local de Saúde de Trás-os-Montes e Alto Douro (PT)
- Rede de Química e Tecnologia (PT)
- Centro de Investigação em Saúde e Ambiente (PT)
- Corresponding author
- Santos, Marlene
- Medeiros, Rui
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-04-04
- Volume
- 24
- Issue
- 7
- Pages
- 6758
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10095078
- OpenAlex
- W4362620113
- Cited by
- 20
- References
- 70
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 3
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Funders
- AstraZeneca Foundation
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- antidepressant response, treatment-resistant depression, major depressive disorder, genetic polymorphism, brain-derived neurotrophic factor, NTRK2, nerve growth factor receptor, CREB1, GSK3B, Akt, MAPK1, mTOR, PTEN, Arc, synapsin I, relapse, neuroplasticity, BDNF/TrkB signaling, mTOR signaling, ERK signaling, synaptic transmission, predictive biomarkers
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Antidepressive Agents, Major Depressive Disorder, Humans, Nerve Tissue Proteins, Phenotype, Recurrence, Cyclic AMP Response Element-Binding Protein, Receptors, Nerve Growth Factor, Brain-Derived Neurotrophic Factor, Mitogen-Activated Protein Kinase 1, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.